51 |
MODULATION OF THE ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR FOLLOWING EXPERIMENTAL RAT BRAIN INJURY IMPROVES CELLULAR AND BEHAVIORAL OUTCOMESWoodcock, Thomas Matt 01 January 2010 (has links)
Traumatic brain injury (TBI) is a leading cause of death and long-term disability worldwide, and survivors are often left with cognitive deficits and significant problems with day to day tasks. To date, therapeutic pharmacological treatments of TBI remain elusive despite numerous clinical trials. An improved understanding of the molecular and cellular response to injury may help guide future treatment strategies. One promising marker for brain injury is the translocator protein (TSPO), which is normally expressed at a low level, but is highly expressed following brain damage and is associated with neuroinflammation. The isoquinoline carboxamide PK11195 binds selectively to the TSPO in many species, and has therefore become the most-studied TSPO ligand. To characterize the time-course of TSPO expression in the controlled cortical injury (CCI) model of TBI we subjected Sprague-Dawley rats to CCI and euthanatized them after 30 minutes, 12 hours, 1, 2, 4, or 6 days. Autoradiography with radiolabelled PK11195 was used to assess the time-course of TSPO binding following CCI. Autoradiographs were compared to adjacent tissue slices stained with the microglia/macrophage marker ED-1, with which a moderate positive correlation was discovered. PK11195 autoradiography was used as a tool with which to assess neuroinflammation following CCI and the administration of an α7 nAChR antagonist, methyllycaconitine (MLA). We hypothesized that blocking the calcium permeable α7 nAChR after brain injury would have a neuroprotective effect by attenuating excitotoxicity in the shortterm. Our study revealed clear dose-dependent tissue sparing in rats administered MLA after trauma and a modest improvement in functional outcome. The relatively modest recovery of function with MLA, which could be due to prolonged α7 nAChR blockade or downregulation lead us to explore the potential of α7 nAChR partial agonists in treating TBI. The α7 nAChR partial agonists tropisetron, ondansetron, and DMXB-A produced a moderate attenuation of cognitive deficits, but did not have a neuroprotective effect on tissue sparing. These studies show that following TBI, α7 nAChR modulation can have neuroprotective effects and attenuate cognitive deficits. Whether this modulation is best achieved through partial agonist treatment alone or a combination antagonist/agonist treatment remains to be determined.
|
52 |
Modulation des récepteurs de l'adénosine par anticorps monoclonaux et ligands synthétiques. : application en physiopathologie humaine / Modulation of adenosine receptors by monoclonal antibody and synthetized ligands : application in human physiopatologyBy, Youlet 12 November 2010 (has links)
L’adénosine est un nucléoside ubiquitaire qui exerce un contrôle puissant sur les systèmes nerveux,immunitaire et cardiovasculaire par l’intermédiaire de quatre récepteurs membranaires : A1R, A2AR, A2BR etA3R. L’étude des récepteurs de l’adénosine est nécessaire à la compréhension de physio‐pathologieshumaines non encore élucidées. Pour étudier l’expression des A2AR, nous avons, dans une première étude,produit un anticorps monoclonal, appelé Adonis, d’isotype IgM, . Adonis reconnait un épitope linéaire desept acides aminés sur la partie C‐terminale de la seconde boucle extra‐cellulaire de l’A2AR humain. Adonisrévèle, par Western blotting sur lysats cellulaires, une bande de 45 KDa, correspondant à l’A2AR. Adonis secomporte comme un « agonist‐like » en augmentant la production d’AMPc et en inhibant la proliférationcellulaire via la stimulation des A2AR. Dans une deuxième étude, nous avons utilisé Adonis pour montrerque l’expression des A2AR de cellules mononucléées, qui mime celle des tissus cardiaques, permet dedifférencier certains patients souffrant de syncope neurocardiogénique. Nous avons monté dans unetroisième étude, qu’Adonis induit une « down‐régulation » de l’expression des co‐récepteurs CXCR4 etCCR5 des cellules T via la stimulation des A2AR, et qu’à ce titre il pouvait être un outil thérapeutique dans lesinfections par HIV. Dans une quatrième étude, nous avons évalué les effets anti‐nociceptifs d’Adonis qui,administré par voie intra‐cérébro‐ventriculaire, augmente de manière dose‐dépendante les latencesobtenues avec le test du Hot‐plate et du Tail‐flick chez la souris. Ces effets sont renversés par deuxantagonistes des A2AR mais aussi par un antagoniste des récepteurs aux opioïdes. Ceci suggère que leseffets anti‐nociceptifs d’Adonis sont médiés par la libération d’opioïdes endogènes. En marge de sesétudes, nous avons également testé les propriétés biologiques de nouveaux ligands des A1R dans le cadred’une collaboration entre chimistes et biologistes. Ainsi, nous montrons, dans une cinquième étude, queparmi la trentaine de molécules synthétisées, quatre sont des antagonistes et deux autres des agonistesavec un EC50 de l’ordre du micromolaire pour la production d’AMPc. De tels agonistes des A1R pourraientêtre utiles dans le traitement des douleurs neuropathiques, tandis que les antagonistes le seraient dansl’insuffisance cardiaque ou utilisés comme diurétique. Enfin dans une sixième étude, nous avons testé unemolécule originale, puisque bivalente, possédant un pôle d’activité pour les récepteurs aux opioïdes μ et unautre pour les A1R. Cette molécule est un antagoniste pour les deux récepteurs. Elle pourrait avoir desapplications cliniques dans certaines pathologies comme le choc hypovolémique ou le sevrage aux opiacés. / Adenosine interacts on its cell surface receptors, namely A1R, A2AR, A2BR and A3R, to exertphysiological effects on target tissues. Modulation of these adenosine receptors appears to be a currenttopic of research which may bring more comprehensions on human pathophysiology yet to be elucidated.In order to study A2AR expression, we produced, in study 1, a monoclonal antibody anti‐human A2AR, calledAdonis being of IgM, isotype. Adonis recognized a linear epitope of seven amino acids on the C‐terminalpart of the A2AR second extra‐cellular loop. By Western blotting, Adonis reveals a 45 KDa band of A2AR incell lysates. Adonis behaves as an agonist‐like which increases the cAMP production and inhibits cellproliferation through A2AR stimulation. In study 2, we showed that using Adonis, to measure the A2ARexpression of peripheral blood mononuclear cells which mimic those of the cardiac tissue, was able todifferentiate some patients with suspected neurally mediated syncope. We showed, in study 3, that A2ARstimulation by Adonis leads to a down‐regulation of CXCR4 and CCR5 expression on T‐cells, suggesting thatAdonis would be a potential drug to treat HIV infections. In study 4, we showed that intracereboventricularinjection of Adonis increased the Hot‐plate and Tail‐flick test latencies in mice in a dose‐dependent manner.Such increases were prevented by two A2AR antagonists and by an opiate receptor antagonist, suggestingthat the anti‐nociceptive effects of Adonis were mediated, at least in part, by endogenous opioid liberation.The last section focused on biological evaluation of new A1R ligands in collaborative studies betweenchemists and biologists. Indeed we showed, in study 5, that among thirty synthesized molecules, four act asA1R antagonists and two turn out to be A1R agonists with a micromolar EC50 on cAMP production. ThoseA1R agonists would be used in neuropathic pains, whereas other antagonists could be used in cardiacfailure or as diuretic. Finally, in study 6, we tested an original hybrid molecule which was revealed to be abivalent antagonist to μ opiate receptors and A1R. This hybrid compound may have applications in somepathologies such as hypovolemic shock and opiate addiction.
|
53 |
Estudos estruturais de novos ligantes sintéticos do receptor PPARY / Structural studies of new synthetic ligands of the PPARY receptorPaula, Karina de 02 October 2017 (has links)
Os receptores nucleares compreendem uma superfamília de proteínas intracelulares reguladas relacionados estruturalmente, capazes de reconhecer sequências específicas de DNA e regulam a transcrição de genes alvos respondendo a sinais metabólicos, hormônios e outras moléculas regulatórias integrando muitas vias de sinalização. Os receptores ativadores da proliferação de peroxissomos (PPARs) são receptores nucleares que regem a transcrição de vários genes envolvidos principalmente no metabolismo de ácidos graxos e energia. A ativação do PPARY possui um amplo aspecto de funções biológicas, regulando o metabolismo, reduzindo a inflamação, influenciando o equilíbrio das células imunes, inibindo a apoptose e o estresse oxidativo e melhorando a função endotelial. Estes efeitos parecem ser benéficos não apenas em diabetes e aterosclerose, mas também em várias outras condições. Os agonistas do PPARY são utilizados como sensibilizadores de insulina para o tratamento da diabetes II, sendo um alvo molecular dos fármacos tiazolidinadionas. Diversos efeitos colaterais severos associados ao uso dos fármacos desta classe e à importância do PPARY no metabolismo de glicose e na sensibilização da insulina, o presente trabalho justifica-se como um esforço para avançar na compreensão da interação entre ligantes sintéticos com o receptor PPARY e a proposição de moléculas mais seguras e mais eficazes para a manutenção de níveis euglicêmicos. Foi realizada a expressão, a purificação, seguida de estudos cristalográficos em cinco ligantes selecionados a partir de etapas de docking realizados anteriormente pelo nosso grupo de Biotecnologia Molecular do Instituto de Física de São Carlos. Os ensaios de cristalização do PPARY complexado a ligantes sintéticos resultaram em duas estruturas cristalográficas que apresentaram uma conformação em que os ligantes não interagiram diretamente na hélice 12 como descritos para agonistas totais do PPARY, adotando características de agonistas parciais. Esses ligantes apresentaram interações hidrofóbicas que estabilizam as fitas-β. Este conjunto de informações estruturais apresentados neste trabalho para o PPARY proporcionou um entendimento das interações que esse receptor é capaz de fazer na presença de um ligante, além de que poderão ser úteis no desenvolvimento de novos moduladores seletivos do PPARY semelhante ao que já se encontram no mercado, porém com efeitos colaterais reduzidos. / Nuclear receptors comprise a superfamily of structurally-related regulated intracellular proteins capable of recognizing specific DNA sequences and regulating the transcription of target genes responding to metabolic signals, hormones and other regulatory molecules integrating many signaling pathways. Peroxisome proliferator-activating receptors (PPARs) are nuclear receptors that govern the transcription of several genes involved primarily in fatty acid and energy metabolism. Activation of PPARY has a broad aspect of biological functions, regulating metabolism, reducing inflammation, influencing immune cell balance, inhibiting apoptosis and oxidative stress, and improving endothelial function. These effects appear to be beneficial not only in diabetes and atherosclerosis, but also in several other conditions. PPARY agonists are used as insulin sensitizers for the treatment of diabetes II, being a molecular target of the thiazolidinediones drugs. A number of severe side effects associated with the use of drugs of this class and the importance of PPARY in glucose metabolism and insulin sensitization, the present work is justified as an effort to advance the understanding of the interaction between synthetic ligands with the PPARY receptor and proposing safer and more effective molecules for the maintenance of euglycemic levels. The expression, purification, followed by crystallographic studies in five ligands selected from docking steps previously performed by our Molecular Biotechnology group of the Physics Institute of São Carlos. The crystallization assays of PPARY complexed to synthetic ligands resulted in two crystallographic structures that exhibited a conformation in which the ligands did not interact directly in helix 12 as described for total PPARY agonists, adopting characteristics of partial agonists. These ligands showed hydrophobic interactions that stabilize the β-ribbons. This set of structural information presented in this work for the PPARY was of great value for the understanding of the interactions that this receptor is able to make in the presence of a ligand, besides that they could be useful in the development of new selective modulators of the PPARY similar to that are already on the market, but with reduced side effects.
|
54 |
Respostas produtivas e expressão gênica induzidas por períodos de fornecimento de ractopamina para suínos em terminação / Production responses and gene expression induced by ractopamine feeding duration for finishing pigsAlmeida, Vivian Vezzoni de 31 August 2012 (has links)
O agonista beta-adrenérgico ractopamina (RAC) modifica a composição da carcaça suína por aumentar a massa muscular e reduzir a deposição de gordura. O objetivo neste estudo foi avaliar os efeitos do tempo de fornecimento de RAC sobre o desempenho, concentração de ureia plasmática (CUP), características de carcaça e expressão gênica dos receptores beta- adrenérgicos (beta-AR) e das isoformas da cadeia pesada de miosina (MyHC) em suínos em terminação. Oitenta suínos, machos castrados (PV inicial = 69,42 ± 1,24 kg), foram utilizados em um experimento em blocos completos casualizados com cinco tratamentos, oito repetições por tratamento e dois animais por unidade experimental (baia). Os tratamentos consistiram de rações sem RAC (controle) ou com 10 ppm de RAC fornecidas por 7, 14, 21 ou 28 dias préabate. O PV individual e o consumo de ração por baia foram obtidos para determinar o ganho diário de peso (GDP), o consumo diário de ração (CDR) e a conversão alimentar (CA). Amostras de sangue foram coletadas para determinação da CUP. No final do experimento, os animais (PV final = 102,46 ± 1,44 kg) foram abatidos e amostras de pelos e do músculo Longissimus dorsi coletadas. As carcaças foram avaliadas 24 horas post-mortem. As amostras de pelos foram utilizadas para detecção da mutação no gene do receptor de rianodina do tipo 1 (RYR1). A expressão gênica dos beta-AR (subtipos beta1 e beta2) e das isoformas MyHC (I, IIa, IIx/d e IIb) foi quantificada nas amostras de músculo. As análises estatísticas foram realizadas apenas com os animais homozigotos dominantes para a mutação no gene do RYR1. O aumento no período de fornecimento de RAC não afetou (P > 0,05) o PV final, o GDP e o CDR, porém resultou em melhora linear (P < 0,01) na CA. Melhoras (P < 0,05) nas médias semanais de GDP e CA foram observadas durante os primeiros 21 dias de fornecimento de RAC, no entanto, o crescimento animal declinou (P < 0,05) na 4ª semana de tratamento. A CUP apresentou efeito quadrático (P < 0,01) com o aumento na duração do fornecimento de RAC. Houve aumento linear (P <= 0,01) no peso da carcaça quente, na profundidade do músculo Longissimus dorsi, na área de olho de lombo e na relação carne:gordura com o aumento na duração do tratamento com RAC. Não foram detectados efeitos da RAC (P > 0,05) sobre a expressão gênica dos beta1-AR e das isoformas MyHC IIa e MyHC IIx/d, porém o aumento no período de fornecimento de RAC tendeu a reduzir linearmente (P = 0,08) a expressão gênica dos beta2-AR. Embora os níveis de RNAm da isoforma MyHC I tenham sido reduzidos linearmente (P < 0,01), a expressão gênica da isoforma MyHC IIb aumentou linearmente (P < 0,01) com o aumento na duração do tratamento com RAC. Portanto, as melhores respostas de desempenho e carcaça ocorreram quando a RAC foi fornecida por 21 e 28 dias, respectivamente. Além disso, o agonista alterou a expressão gênica das isoformas MyHC, e é possível que a ação da RAC esteja relacionada com a população de beta2-AR. / The beta-adrenergic agonist ractopamine (RAC) modifies the swine carcass composition by increasing muscle mass and decreasing fat deposition. The objective in this study was to evaluate the effects of RAC feeding duration on performance, plasma urea nitrogen (PUN) concentration, carcass traits, and gene expression of beta-adrenergic receptors (beta-AR) and myosin heavy chain (MyHC) isoforms in finishing pigs. Eighty barrows (initial BW = 69.42 ± 1.24 kg) were used in a randomized complete block design experiment with five treatments, eight replicates per treatment, and two animals per experimental unit (pen). The dietary treatments consisted of diets containing no RAC (control) or 10 ppm RAC fed for 7, 14, 21, or 28 days before slaughter. Individual pig BW and pen feed disappearance were obtained to determine average daily gain (ADG), average daily feed intake (ADFI), and feed to gain ratio (F:G). Blood samples were collected for determination of PUN concentrations. At the end of the experiment, pigs (final BW = 102.46 ± 1.44 kg) were slaughtered and hair and Longissimus dorsi muscle samples collected. The carcasses were evaluated 24 hours postmortem. Hair samples were used to detect the mutation of the ryanodine receptor type 1 (RYR1) gene. Gene expression of beta-AR (beta1- and beta2-subtypes) and MyHC isoforms (I, IIa, IIx/d, and IIb) was quantified in the muscle samples. Statistical analyses were performed using only the homozygous dominant pigs for the RYR1 gene mutation. Increasing RAC feeding period did not affect (P > 0.05) final BW, ADG, and ADFI, but resulted in a linear improvement (P < 0.01) in F:G. Average weekly improvements (P < 0.05) in ADG and F:G were observed during the first 21 days of RAC feeding, however, animal growth declined (P < 0.05) in the 4th week of treatment. The PUN concentrations showed a quadratic effect (P < 0.01) as RAC feeding duration increased. There were linear increases (P <= 0.01) in hot carcass weight, Longissimus dorsi muscle depth, loin eye area, and muscle to fat ratio as RAC treatment duration increased. No effects of RAC feeding (P > 0.05) were detected for beta1-AR and for isoforms of MyHC IIa and MyHC IIx/d gene expression, but increasing RAC feeding period tended to linearly decrease (P = 0.08) beta2-AR gene expression. Even though mRNA levels of MyHC I isoform decreased linearly (P < 0.01), gene expression of MyHC IIb isoform increased linearly (P < 0.01) as RAC treatment duration increased. Therefore, greater growth and carcass responses occurred when RAC was fed for 21 and 28 days, respectively. Furthermore, the agonist altered the MyHC gene expression and the RAC action may be related to the beta2-AR population.
|
55 |
Efeito do agonista seletivo do receptor canabinoide 1 (CB1) em modelos de neurodegeneração induzida pela estreptozotocina. / The effect of cannabinoid receptor 1 (CB1) selective agonist on models of streptozotocin-induced neurodegeneration.Crunfli, Fernanda 13 December 2017 (has links)
A doença de Alzheimer (DA) é caracterizada por déficit cognitivo, associada com prejuízos no metabolismo energético e na via de sinalização da insulina encefálicos. A injeção intracerebroventricular de baixas doses de estreptozotocina (STZ) tem sido utilizada como um modelo experimental da DA em ratos. Nesse sentido, tem sido demonstrada a participação do sistema canabinoide em processos neurodegenerativos e seus efeitos neuroprotetores e anti-inflamatórios. O objetivo deste trabalho foi caracterizar as alterações comportamentais e moleculares em modelos experimentais (in vivo e in vitro) expostos à STZ e avaliar a participação do sistema canabinoide. A STZ produziu prejuízo cognitivo, morte celular por apoptose, deficiência na resposta à insulina e alterações na via IR/PI3K, semelhantes às encontradas na DA. O agonista canabinoide ACEA foi capaz de reverter o prejuízo cognitivo, modificar as alterações proteicas da via IR/PI3K, e regular positivamente a via anti-apoptótica, gerando uma neuroproteção. / Alzheimer\'s disease (AD) is characterized by cognitive deficit associated with energy metabolism impairment and changes in insulin signaling. In this context, low doses of intracerebroventricular streptozotocin (STZ) injection has been used as an experimental model of AD in rats. Several studies have demonstrated the participation of the cannabinoid system in neurodegenerative processes and its neuroprotective and anti-inflammatory properties. Thus, the aim of this work was to characterize the molecular and behavior alterations in experimental models (in vitro and in vivo) produced by STZ exposure and evaluate the cannabinoid system participation in these models. STZ was able to induce cognitive impairment, apoptosis cell death, impaired insulin response and alterations in the IR/PI3K signaling pathway, similar to those found in AD. CB1 agonist, ACEA reversed cognitive impairment and modified some protein changes in IR/PI3K pathway caused by STZ, and positively regulate the anti-apoptotic pathway, generating neuroprotection.
|
56 |
Efeitos do período de administração de cloridrato de zilpaterol e do tempo de confinamento no desempenho, características de carcaça e qualidade de carne de bovinos Nelore / Effects of zilpaterol hydrochloride feeding time and feedlot days on performance, carcass characteristics and meat quality of Nellore bullsSantos, Antonio Carlos Ramos dos 27 February 2015 (has links)
O objetivo desta pesquisa foi avaliar os efeitos do período de administração de cloridrato de zilpaterol (CZ) e do tempo de confinamento no desempenho, características de carcaça, rendimento de cortes cárneos comerciais e na qualidade de carne de bovinos Nelore. Foram utilizados 96 bovinos machos não castrados da raça Nelore, com peso vivo inicial de 377 ± 25,1 kg. O delineamento utilizado foi o de blocos completos casualizados em esquema fatorial 4 × 2, sendo quatro períodos de administração com CZ (0, 20, 30 ou 40 dias) e dois tempos de confinamento (90 ou 117 dias). O período de suplementação com CZ (8,33 mg/kg de matéria seca total) iniciou-se 23, 33 e 43 dias antes do abate. Nos últimos três dias que antecederam o abate todos os animais foram alimentados com a dieta sem CZ, respeitando o período de carência do produto. O contrafilé (músculo Longissimus thoracis et lumborum) de todas as meias-carcaças esquerdas foi amostrado para as análises de qualidade de carne. Com exceção da área do olho de lombo obtida por ultrassom (P = 0,02) e área do olho de lombo medida na carcaça resfriada (P = 0,05), não houve interação entre período de administração de CZ e tempo de confinamento (P > 0,10). O aumento do período de suplementação com CZ proporcionou aumento linear da eficiência alimentar (P < 0,01), peso de carcaça quente (P < 0,01), rendimento de carcaça quente (P < 0,01) e rendimento de carne desossada (P < 0,01). Os bifes de contrafilé de animais suplementados com CZ apresentaram maior conteúdo percentual de proteína (P < 0,01), enquanto que a espessura de gordura subcutânea (P = 0,04) e o conteúdo percentual de lipídios intramusculares (P < 0,01) diminuíram com administração de CZ. O valor percentual de ácidos graxos poliinsaturados totais aumentou (P = 0,01) com a administração de CZ, sendo atribuído principalmente ao aumento percentual do ácido linoleico (18:2 cis-9, cis-12; P = 0,01) e ácido araquidônico (20:4 n-6; P < 0,01). A força de cisalhamento das amostras de contrafilé aumentou (P < 0,01) com a inclusão de CZ na dieta, sendo esse resultado independente do tempo de maturação (7, 14, 21 ou 28 dias post-mortem). Observou-se interação entre período de administração de CZ e tempo de maturação (14 ou 28 dias post-mortem) para escore de maciez inicial (P = 0,03) e escore de tecido conjuntivo (P < 0,01), onde o processo de maturação melhorou mais a carne de animais controle do que a carne de animais suplementados com CZ. Mesmo com a diminuição da maciez, os bifes de animais suplementados com CZ foram considerados macios pelos provadores do painel sensorial. O CZ melhora a eficiência de produção de carne de bovinos Nelore, proporcionando aumento na massa muscular dos animais tratados sem alterar o consumo de matéria seca. Por outro lado, o tratamento dos animais com CZ reduz a maciez e a velocidade do processo de amaciamento do contrafilé. / The objective of this research was to evaluate the effects of zilpaterol hydrochloride (ZH) feeding time and feedlot days on performance, carcass characteristics, yield commercial cuts and meat quality of Nellore bulls. Ninety six Nellore bulls with initial body weight of 377 ± 25.1 kg were used in a randomized complete block in 4 × 2 factorial design, with four periods of ZH feeding (0, 20, 30 or 40 d) and 90 or 117 d in the feedlot. The supplementation period with ZH (8.33 mg/kg of dietary dry matter basis) started 23, 33 or 43 d before slaughter. In the last three days prior to slaughter all the animals were fed the diet without ZH, respecting the product grace period. Strip loin (m. Longissimus thoracis et lumborum) of all left-carcases were sampled for meat quality analysis. With the exception of LM area obtained both by ultrasound (P = 0.02) and by refrigerated carcasses (P = 0.05), there was no interaction between periods ZH feeding and days in the feedlot (P > 0.10). The increase of the supplementation period with ZH linearly increased feed efficiency (P < 0.01), hot carcass weight (P < 0.01), hot carcass yield (P < 0.01) and boning yield (P < 0.01). Beef strip loin steaks from animals supplemented with ZH presented a higher percentage of protein content (P < 0.01), while the 12th-rib fat (P = 0.04) and the percentage content of intramuscular fat (P < 0.01) decreased with ZH feeding. The percentage of polyunsaturated fatty acids increased (P = 0.01) with the ZH feeding and was mainly attributed to the increase of linoleic acid (18:2 cis-9, cis-12; P = 0.01) and arachidonic acid (20:4 n-6, P < 0.01). The Warner-Bratzler shear force (P < 0.01) from the strip loin samples increased with the inclusion of dietary ZH and this result was independent of the aging time (7, 14, 21 or 28 d postmortem). There was interaction between ZH feeding period and maturation time (14 or 28 d postmortem) to initial tenderness score (P = 0.03) and connective tissue score (P < 0.01), showing that the maturation process improved meat tenderness of control animals rather than ZH animals. Despite the initial meat tenderness decrease, strip loin steaks of animals supplemented with ZH were still considered tender by trained evaluators. ZH improves Nellore bulls meat production efficiency, providing an increase in muscle mass of the treated animals with no change in dry matter intake. However, treatment of animals with ZH reduces the tenderness and the speed of the strip loin maturation process.
|
57 |
TGR5, cible thérapeutique pour le traitement du diabète de type 2 et ses complications métaboliques : de la chimie aux effets biologiques / TGR5, therapeutic target for the treatment of diabetes mellitus and its metabolic complications : from chemistry to biological effectsLasalle, Manuel 09 October 2015 (has links)
Les acides biliaires sont depuis longtemps connus pour leur propriété d’agents solubilisant des graisses et des vitamines liposolubles, permettant ainsi une absorption efficace de ces nutriments lors de la digestion. Depuis les années 2000, plusieurs équipes ont montré que ces molécules étaient également dotées de propriétés de signalisation, en particulier via l’activation de deux récepteurs : le récepteur nucléaire FXR, et le récepteur membranaire TGR5. Le récepteur TGR5 est exprimé dans de très nombreux tissus, dont les muscles lisses et squelettiques, le tissu adipeux brun, la vésicule biliaire, mais aussi certaines cellules immunitaires et certaines populations cellulaires intestinales telles que les cellules entéroendocrine L. Selon le tissu étudié, l’activation de TGR5 peut être suivie de nombreux effets biologiques. En particulier, au niveau intestinal, l’activation de ce récepteur stimule la sécrétion de l’hormone incrétine GLP-1.Les hormones incrétines sont impliquées dans la régulation de la glycémie, en particulier dans la phase postprandiale, où elles concourent à potentialiser l’action de l’insuline, hormone hypoglycémiante majeure. Or, dans un contexte de diabète, et en particulier de diabète de type 2, l’organisme est devenu moins sensible à l’insuline, ce qui se traduit par un défaut de gestion de la glycémie, pouvant entrainer à terme des complications graves, telles que des amputations, une cécité, ou encore des problèmes cardiovasculaires. La prévalence et l’incidence de cette pathologie ont conduit l’OMS à la considérer comme la première épidémie d’origine non-infectieuse, ce qui illustre son impact sur la santé publique et le besoin médical constant qu’elle génère.Dans ce contexte, TGR5 apparait comme cible thérapeutique potentielle attrayante, de par l’effet GLP-1 sécrétagogue consécutif à son activation. En effet, parmi les thérapies antidiabétiques, deux classes de molécules basent leur efficacité sur une augmentation de la signalisation de la voie incrétine : les incrétinopotentiateurs (inhibiteurs de la DDP4, enzyme responsable de la faible demi-vie du GLP-1) et les incrétinomimétiques (agonistes synthétiques du récepteur au GLP-1). Récemment, cette dernière classe a également fait son apparition dans l’arsenal thérapeutique de l’obésité, confirmant l’intérêt de cette voie de signalisation dans les pathologies issues d’un désordre métabolique. L’obtention de composés GLP-1 sécrétagogues s’avère ainsi prometteuse et représente une approche complémentaire aux deux autres classes.L’objectif de ce travail était donc d’obtenir des agonistes puissants, sélectifs et originaux du récepteur TGR5. Afin de diminuer les risques d’effets indésirables, on-target ou off-target, nous avons choisi de profiter de la localisation intestinale de notre cible d’intérêt en concevant nos composés de manière à limiter l’exposition au seul tractus gastro-intestinal, en limitant leur absorption. Ainsi, nous avons cherché à obtenir des composés non systémiques GLP-1 sécrétagogues.La stratégie employée pour aboutir à ces composés a été le développement de molécules chimériques constituées d’une partie agoniste de TGR5, le pharmacophore, liée à un groupement permettant de limiter la perméabilité membranaire et donc l’absorption intestinale, le kinétophore. Après avoir optimisé la partie pharmacophore et identifié une position permettant l’ajout de différents types de kinétophores sans impact majeur sur l’activité du composé, nous avons pu obtenir plusieurs agonistes de TGR5 puissants, originaux, et dotés d’une très faible perméabilité membranaire. L’étude in vivo de ces molécules a ensuite permis de valider d’une part leur activité GLP-1 sécrétagogue, et d’autre part leur faible exposition systémique. Enfin, l’évaluation du potentiel thérapeutique d’un des meilleurs composés dans des modèles murins de diabète a récemment pu être initiée. / Bile acids have long been known as lipid solubilizing agents, enabling efficient absorption of nutrients and vitamins during digestion. Since 2000, several teams have demonstrated the signaling properties of these molecules, especially through the activation of two receptors : the nuclear receptor FXR and the membrane receptor TGR5.The TGR5 receptor is expressed in various tissues, such as smooth and skeletal muscles, brown adipose tissue, gallbladder, but also on some immune or intestinal cell lines such as the enteroendocrine L cells. Depending on the studied tissue, TGR5 activation can trigger various biological effects. In the intestine, its activation can stimulate the secretion of an incretin hormone, the GLP-1.Incretin hormones play a role in glycaemia regulation, especially during the postprandial phase during which they potentiate the action of the insulin, the main hypoglycemic hormone. Diabetes mellitus correspond to a decreased response of the organism to insulin signaling. This leads to a default in the glycaemia handling that can lead to serious complications, such as amputation, blindness, or cardiovascular problems. Prevalence and incidence of this disease have lead the WHO to define diabetes as the first non-infectious epidemic, illustrating its impact on public health and the constant need for new therapeutic opportunities.In this context, TGR5 appears as an appealing potential therapeutic target, especially because of the GLP-1 secretagogue effect triggered by its activation. Indeed, among the antidiabetic therapeutic options, two classes of drugs work by increasing the incretin signaling: the incretinopotentiators (inhibitors of the DPP4, which is the enzyme responsible for the very short half-life of GLP-1), and the incretinomimetics (synthetic agonists of the GLP-1 receptor). Recently, this last class has also been approved to treat obesity. This demonstrates the interest of this signaling pathway in the treatment of metabolic disorders. Hence, GLP-1 secretagogue compounds may prove to be an interesting approach, and could complement the two other classes.The aim of this work was then to obtain potent, selective and original agonists of the TGR5 receptor. In order to decrease the risk of on-target and off-target effects, we decided to take advantage of the intestinal localization of our target by designing compounds that would only expose the gastro-intestinal tract, by limiting their absorption. Thus, we wanted to obtain non systemic GLP-1 secretagogue compounds.Our strategy was to develop chimeric compounds consisting of a pharmacophore part, which would be a potent and selective agonist of TGR5, linked to a kinetophore part, which would decrease membrane permeability. After having optimized the pharmacophore part and having identified a position where we could link various kinetophore moieties with only weak impact on the activity, we obtained several potent TGR5 agonists with very low membrane permeability. In vivo evaluations of these compounds have validated both their GLP-1 secretagogue activity and their low systemic exposure. In the end, evaluation of our lead compound on mouse model of diabetes was recently started.
|
58 |
Estudos estruturais de novos ligantes sintéticos do receptor PPARY / Structural studies of new synthetic ligands of the PPARY receptorKarina de Paula 02 October 2017 (has links)
Os receptores nucleares compreendem uma superfamília de proteínas intracelulares reguladas relacionados estruturalmente, capazes de reconhecer sequências específicas de DNA e regulam a transcrição de genes alvos respondendo a sinais metabólicos, hormônios e outras moléculas regulatórias integrando muitas vias de sinalização. Os receptores ativadores da proliferação de peroxissomos (PPARs) são receptores nucleares que regem a transcrição de vários genes envolvidos principalmente no metabolismo de ácidos graxos e energia. A ativação do PPARY possui um amplo aspecto de funções biológicas, regulando o metabolismo, reduzindo a inflamação, influenciando o equilíbrio das células imunes, inibindo a apoptose e o estresse oxidativo e melhorando a função endotelial. Estes efeitos parecem ser benéficos não apenas em diabetes e aterosclerose, mas também em várias outras condições. Os agonistas do PPARY são utilizados como sensibilizadores de insulina para o tratamento da diabetes II, sendo um alvo molecular dos fármacos tiazolidinadionas. Diversos efeitos colaterais severos associados ao uso dos fármacos desta classe e à importância do PPARY no metabolismo de glicose e na sensibilização da insulina, o presente trabalho justifica-se como um esforço para avançar na compreensão da interação entre ligantes sintéticos com o receptor PPARY e a proposição de moléculas mais seguras e mais eficazes para a manutenção de níveis euglicêmicos. Foi realizada a expressão, a purificação, seguida de estudos cristalográficos em cinco ligantes selecionados a partir de etapas de docking realizados anteriormente pelo nosso grupo de Biotecnologia Molecular do Instituto de Física de São Carlos. Os ensaios de cristalização do PPARY complexado a ligantes sintéticos resultaram em duas estruturas cristalográficas que apresentaram uma conformação em que os ligantes não interagiram diretamente na hélice 12 como descritos para agonistas totais do PPARY, adotando características de agonistas parciais. Esses ligantes apresentaram interações hidrofóbicas que estabilizam as fitas-β. Este conjunto de informações estruturais apresentados neste trabalho para o PPARY proporcionou um entendimento das interações que esse receptor é capaz de fazer na presença de um ligante, além de que poderão ser úteis no desenvolvimento de novos moduladores seletivos do PPARY semelhante ao que já se encontram no mercado, porém com efeitos colaterais reduzidos. / Nuclear receptors comprise a superfamily of structurally-related regulated intracellular proteins capable of recognizing specific DNA sequences and regulating the transcription of target genes responding to metabolic signals, hormones and other regulatory molecules integrating many signaling pathways. Peroxisome proliferator-activating receptors (PPARs) are nuclear receptors that govern the transcription of several genes involved primarily in fatty acid and energy metabolism. Activation of PPARY has a broad aspect of biological functions, regulating metabolism, reducing inflammation, influencing immune cell balance, inhibiting apoptosis and oxidative stress, and improving endothelial function. These effects appear to be beneficial not only in diabetes and atherosclerosis, but also in several other conditions. PPARY agonists are used as insulin sensitizers for the treatment of diabetes II, being a molecular target of the thiazolidinediones drugs. A number of severe side effects associated with the use of drugs of this class and the importance of PPARY in glucose metabolism and insulin sensitization, the present work is justified as an effort to advance the understanding of the interaction between synthetic ligands with the PPARY receptor and proposing safer and more effective molecules for the maintenance of euglycemic levels. The expression, purification, followed by crystallographic studies in five ligands selected from docking steps previously performed by our Molecular Biotechnology group of the Physics Institute of São Carlos. The crystallization assays of PPARY complexed to synthetic ligands resulted in two crystallographic structures that exhibited a conformation in which the ligands did not interact directly in helix 12 as described for total PPARY agonists, adopting characteristics of partial agonists. These ligands showed hydrophobic interactions that stabilize the β-ribbons. This set of structural information presented in this work for the PPARY was of great value for the understanding of the interactions that this receptor is able to make in the presence of a ligand, besides that they could be useful in the development of new selective modulators of the PPARY similar to that are already on the market, but with reduced side effects.
|
59 |
Comparing Family Planning Knowledge Among Females and Males Receiving Opioid Agonist Treatment or Seeking Primary Care ServicesMelbostad, Heidi S. 01 January 2019 (has links)
Background: Approximately 70% of US adults currently receiving opioid agonist treatment (OAT) for opioid use disorder are of reproductive age. Among women receiving OAT at risk of having an unintended pregnancy, typically less than half report any current contraceptive use compared to 90% in the general population. In addition, the rate of unintended pregnancy among women receiving OAT is disproportionately higher than the general population (~80% vs. 45%, respectively). Lack of knowledge about family planning may be contributing to decreased rates of contraceptive use and increased rates of unintended pregnancy among women receiving OAT.
Method: Participants were a convenience sample of women and men receiving OAT or a comparison group receiving primary care (PC) services. Family planning knowledge was assessed with the recently validated Contraceptive Knowledge Assessment (CKA), a self-administered 25-question multiple-choice survey. A two-way ANOVA, with fixed factors (i.e. patient sample and sex), compared the total number of correct responses for all questions and five more specific content areas (p<.05).
Results: Overall, 332 participants completed this survey. The mean percent of total correct responses was significantly lower in the OAT sample (n=167) compared to the PC sample (n=165), 47% vs. 53% correct, respectively (p<.001) or approximately 1.5 questions less. The mean percent of correct responses in four of the five content areas was also lower among the OAT sample compared to the PC sample (ps<.01). The mean percent of total correct responses was significantly higher among women (n=169) than men (n=163), 56% vs. 44% correct, respectively (p<.0001) or approximately 3 questions more. The percent of correct responses in four of the five content areas was also higher among women than men (ps<.01).
Conclusion: Given the substantial discrepancy in rates of contraceptive use and unintended pregnancy between individuals receiving OAT and the general population, it is somewhat unexpected that individuals receiving OAT did not have lower levels of family planning knowledge, although patients in both samples only answered approximately 50% of the questions correctly. Results from the present study suggest deficits in family planning knowledge, while statistically significant, may be less clinically so. Overall, lack of family planning knowledge is likely only playing a small role in population differences in contraceptive use and unintended pregnancy and interventions aimed at decreasing these differences will need to address other barriers to accessing family planning services and utilizing contraception in this population.
|
60 |
Wirksamkeit und Verträglichkeit des Dopamin-Agonisten Ropinirol bei jungen Patienten mit hyperkinetischer Störung / Efficacy and safety of the dopamine agonist ropinirole in the treatment of boys with attention deficit hyperactivity disorderClaus, Armin January 2013 (has links) (PDF)
Die Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) ist eine häufige Erkran-kung bei Kindern und Jugendlichen. Vor allem bei Ausbleiben einer suffizienten Be-handlung verursacht die ADHS sehr oft vielfältige Probleme, die das Leben der Be-troffenen in Familie, Schule und Freizeit gravierend beeinträchtigen. Zahlreiche Studien beschreiben eine Dysfunktion des dopaminergen Systems als Hauptursache für das Auf-treten der Kardinalsymptome Hyperaktivität, Konzentrationsmangel und Impulsivität. Die Hauptsäule der medikamentösen Behandlung ist das zwingend per Betäubungsmit-telrezept zu verordnende Stimulanz METHYLPHENIDAT mit eigenem Nebenwir-kungsprofil und einer nicht geringen Rate an Nonrespondern.
Einzelne Literaturstellen und theoretische Vorüberlegungen lassen eine Korrektur dys-funktionaler dopaminerger Transmitterprozesse bei ADHS nicht allein durch Stimulanzi-en, sondern auch durch die Klasse der Dopamin-Agonisten denkbar erscheinen. Diese Vorüberlegungen basieren u. a. auf den Kenntnissen der Eigenschaften und des Wirkmechanismus des Dopamin-Agonisten ROPINIROL, der vielfach in der Behandlung der Parkinson-Krankheit eingesetzt wird.
Dieser Heilversuch ist die erste prospektive Untersuchung zur Sicherheit und Wirksam-keit des Dopamin-Agonisten ROPINIROL in der Behandlung von jungen männlichen ADHS-Patienten. Gleichzeitig liegt damit auch der erste Wirksamkeitsvergleich des erstmals gezielt zur ADHS-Behandlung eingesetzten Wirkstoffes ROPINIROL mit der Goldstandard-Substanz der ADHS-Medikation, nämlich METHYLPHENIDAT vor.
Insgesamt nahmen 9 Jungen mit ADHS im Alter zwischen 8 und 13 Jahren an dem Heilversuch teil, 3 dieser 9 Probanden im Rahmen eines Vortests, die übrigen 6 unter den Bedingungen des endgültigen Heilversuchs. Die Effekte der jeweils eingesetzten Substanz auf die Symptomausprägung der ADHS wurden mit Hilfe der Kurzform des Eltern-Lehrer-Fragebogens nach Conners und speziell hinsichtlich der ADHS-relevanten Verhaltensparameter Konzentrationsfähigkeit und Impulskontrolle durch den computer-gestützten Continuous Performance Test, CPT, erhoben.
Im Bild der angewandten computergestützten Konzentrations- und Impulskontroll-belastungstests (CPT) ergab sich bei 2 der 6 Probanden des Hauptheilversuches unter ROPINIROL eine sehr deutliche Verbesserung der Konzentration (Steigerung der rich-tigen Tastendrücke um 30% bzw. 70%). In der Betrachtung der gesamten Probanden-gruppe war der die Konzentration fördernde Effekt von ROPINIROL aber unspezifisch (p=0,463) und blieb weit hinter dem statistisch signifikanten konzentrationsfördernden Effekt von METHYLPHENIDAT auf die Probandengruppe (p=0,021) zurück.
5 von 6 Probanden handelten unter ROPINIROL weniger impulsiv und reduzierten die Anzahl falscher Tastendrücke im CPT gering bis deutlich. 3 dieser 5 Probanden verrin-gerten diese Fehlerzahl unter ROPINIROL um mindestens 40% der Ausgangsfehlerzahl ohne Medikation.
Anders als beim Verhaltensparameter Konzentration ließ sich hinsichtlich der Impuls-kontrolle kein Nachteil der Medikation mit ROPINIROL gegenüber METHYLPHENI-DAT errechnen.
Auch in der Auswertung der Kurzform des Eltern-Lehrer-Fragebogens nach Conners war ROPINIROL METHYLPHENIDAT rechnerisch nicht signifikant unterlegen. We-gen der kleinen Probandengruppe in Verbindung mit der deutlichen Streubreite der Er-gebnisse zur Impulsivität und innerhalb der Conners-Skalen kann dies aber bestenfalls als Hinweis, nicht aber als rechnerisch bewiesene Ähnlichkeit der Wirkstärke beider Substanzen in der Verbesserung vor allem der Impulskontrolle interpretiert werden.
6 von 9 Probanden beschrieben unter Ropinirol spürbare Tagesmüdigkeit. Diese war unter den höheren Dosen Ropinirol des Vortestes (max. 2mg ROP/die) besonders häufig und stark (3 von 3 Probanden). Unter der reduzierten Enddosis von maximal 1mg ROP/die im Haupttest lag die Häufigkeit der Tagesmüdigkeit bei 4 von 6 Probanden und wurde weniger stark erlebt. Dies weist auf eine Dosisabhängigkeit dieser im Heil-versuch am häufigsten registrierten unerwünschten Wirkung von Ropinirol hin. Impera-tive Schlafattacken blieben vollständig aus.
Der Beweis für das Potential des Dopamin-Agonisten ROPINIROL, die Symptome einer ADHS in ähnlichem Ausmaß wie das Stimulanz METHYLPHENIDAT zu verrin-gern oder zumindest statistisch fassbar zu reduzieren, konnte in der Gesamtwürdigung der Ergebnisse dieses Heilversuchs nicht erbracht werden. Es ergaben sich aber einzelne Hinweise auf eine Teilwirksamkeit von ROPINIROL gegen ADHS-Symptome bei einzelnen Probanden, vor allem für den Symptombereich der Impulsivi-tät. Hinweise auf ein Nebenwirkungsprofil, das jede zukünftige Anwendung von ROPINIROL bei ADHS-Erkrankten ausschließt, wurden nicht festgestellt.
Die mit Hilfe dieses pilotstudienartigen Heilversuchs gewonnenen Erkenntnisse könnten durch breiter angelegte Studien z. B. im Design einer randomisierten doppelblinden Wirksamkeitsvergleichsstudie überprüft und weiterentwickelt werden, um die mögliche Eignung von Dopamin-Agonisten wie Ropinirol als medikamentöse Alternative für be-stimmte Subpopulationen von ADHS-Betroffenen besser beurteilen zu können. / Efficacy and safety of the dopamine agonist ropinirole in the treatment of boys with attention deficit hyperactivity disorder
|
Page generated in 0.0943 seconds